



17th  
**ICML**

**International  
Conference  
on Malignant  
Lymphoma**  
Lugano

June  
13-17  
2023

# Program Book

The program is subject to changes,  
for updates visit [www.icml.ch](http://www.icml.ch)

Organized by In cooperation with




**AAGR** American Association  
for Cancer Research®  
FINDING CURES TOGETHER™



**ESMO** GOOD SCIENCE  
BETTER MEDICINE  
BEST PRACTICE






# INDEX

Acknowledgements	2
General Information	4
17-ICML locations and floorplans	6
- Palazzo dei Congressi	
- Il Ciani building	
- Marquee	
- Villa Ciani	
- Other 17-ICML locations	
ICML Climate Impact	17
Program at a glance	18
Corsa della speranza (Run for Hope) - ICML edition	23
Conference Program	24
Transportations	60
Contacts	61

**SAVE THE DATE**



18th  
**ICML**

**International  
Conference  
on Malignant  
Lymphoma**  
Lugano

June  
17-21  
2025

© Andrea Pini  
Illustration

# ACKNOWLEDGEMENTS

## **INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA (ICML) and FOUNDATION FOR THE INSTITUTE OF ONCOLOGY RESEARCH (IOR) PRESIDENT**

Franco Cavalli, Bellinzona (Switzerland)

## **ICML ORGANIZING COMMITTEE CHAIRMAN**

Francesco Bertoni, Bellinzona (Switzerland)

## **ICML ORGANIZING COMMITTEE**

Francesco Ceppi

Adalgisa Condoluci

Alden Moccia

Bertrand Nadel, Marseilles (France) -

*Representative of American Association  
for Cancer Research (AACR)*

Fedro Peccatori, Milan (Italy) -

*Representative of European School of Oncology  
(ESO)*

Maria Cristina Piroso

Davide Robbiani

Davide Rossi

Anastasios Stathis

Georg Stüssi

Doris Vola, Lugano (Switzerland) -

*Representative of European Society  
for Medical Oncology (ESMO)*

Emanuele Zucca

## **CONFERENCE SECRETARIAT**

Cristiana Brentan, Federica Cariglia, Orietta Lugli,

Stéphanie Pedrioli, Chiara Saporiti

Foundation for the Institute of Oncology Research

(IOR) Via Vela 6, CH-6500 Bellinzona

## **17-ICML ADVISORY BOARD**

Ranjana H. Advani, Palo Alto, CA (USA)

James O. Armitage, Omaha, NE (USA) – *Chairman*

Helmut Beltraminelli, Locarno (Switzerland)

Elias Campo, Barcelona (Spain)

Bruce D. Cheson, Bethesda, MD (USA)

Nicholas Chiorazzi, Manhasset, NY (USA)

Wee Joo Chng, Singapore (Singapore)

Riccardo Dalla-Favera, New York, NY (USA)

Stephan Dirnhofer, Basel (Switzerland)

Martin Dreyling, Munich (Germany)

Jonathan W. Friedberg, Rochester, NY (USA)

Mary K. Gospodarowicz, Toronto, ON (Canada)

Peter W.M. Johnson, Southampton (UK)

Brad S. Kahl, St. Louis, MO (USA)

Won Seog Kim, Seoul (South Korea)

Marco Ladetto, Alessandria (Italy)

John P. Leonard, New York, NY (USA)

T. Andrew Lister, London (UK)

Stefano Luminari, Reggio Emilia (Italy)

Ari M. Melnick, New York, NY (USA)

Urban Novak, Bern (Switzerland)

Grzegorz S. Nowakowski, Rochester, MN (USA)

Koichi Ohshima, Kurume (Japan)

Astrid Pavlovsky, Buenos Aires (Argentina)

Leticia Quintanilla de Fend, Tübingen (Germany)

Gilles Salles, New York, NY (USA)

Kerry J. Savage, Vancouver, BC (Canada)

John F. Seymour, Melbourne (Australia)

Lena Specht, Copenhagen (Denmark)

Catherine Thieblemont, Paris (France)

Wilhelm Wössmann, Hamburg (Germany)

Thorsten Zenz, Zurich (Switzerland)

Weili Zhao, Shanghai (China)

Pier Luigi Zinzani, Bologna (Italy)

**The Organizers would like to express their sincere gratitude to the Industry Partners who continue to support the Conference. Their unrestricted support is essential to the dissemination of the Scientific and Industry programs to the worldwide community engaged in the study and treatment of lymphoid neoplasms:**

AbbVie

Acrotech Biopharma, Inc.

AstraZeneca

BeiGene

Bristol Myers Squibb

CRISPR Therapeutics

Eli Lilly and Company

EUSA Pharma (UK) Ltd.

Genexpath

Genmab

Incyte

Janssen

Kite, A Gilead Company

Gilead and Kite Oncology

Kyowa Kirin

Miltenyi Biomedicine

MSD

Novartis

Pierre Fabre

Regeneron

Roche

Sobi

Takeda

Viracta

*(updated on May 2023)*

**The Organizers would like to express their sincere gratitude to the following Partners for their precious support, essential to the organization of our Conference and to the achievement of its objectives:**

Agenzia Turistica Ticinese SA

American Association for Cancer Research – AACR

City of Lugano

European Society for Medical Oncology – ESMO

European School of Oncology – ESO

Follicular Lymphoma Foundation – FLF

IBSA Foundation for Scientific Research

International Extranodal Lymphoma Study

Group - IELSG

International Lymphoma Radiation Oncology

Group – ILROG

Lugano Region

Saudi Society of Blood & Marrow Transplantation

- SS-BMT

Swiss Cancer League

Swiss Cancer Research foundation

Union of Chinese lymphoma Investigators – UCLI

Università della Svizzera Italiana - USI

*(updated on May 2023)*

# GENERAL INFORMATION

17-ICML participants will be able to download the certificate of attendance from the 17-ICML Virtual Platform (My Profile section), after completing the evaluation form.

ICML is not accredited with European CME.

## 17-ICML Educational Book

Articles of the Educational Symposia and Meet the Professor sessions are included in the 17-ICML Educational Book, supplement to “Hematological Oncology” and published by Wiley. The supplement is distributed to attendees on site and also available online at the ICML official website ([www.icml.ch](http://www.icml.ch)) and at the Wiley Online Library website (<http://onlinelibrary.wiley.com>). The 17-ICML Educational book production has been supported by an unrestricted educational grant of Takeda.

## 17-ICML Abstract Book

All selected abstracts are included in the 17-ICML Abstract Book, published by Wiley and available online at the ICML website ([www.icml.ch](http://www.icml.ch)) and at the Wiley Online Library website (<http://onlinelibrary.wiley.com>).

## Travel Grants

A limited number of travel grants, sponsored by the Swiss Cancer League and by the ICML Organizing Committee, are provided to young investigators (less than 35 years old), whose abstract has been accepted for an oral or poster presentation.

The selection was made on the basis of the abstract evaluation results.

Congratulations to the following young investigators:

Jan-Paul Bohn, Innsbruck, AT	presentation nr 117
Berit Brinkmann, Heidelberg, DE	presentation nr 128
Paul Jan Bröckelmann, Cologne, DE	presentation nr 104
Dana Casey, Chapel Hill, NC, US	presentation nr 034
Anja Fischer, Ulm, DE	presentation nr 122
Ayumi Fujimoto, Tokyo, JP	presentation nr 239
Jan-Michel Heger, Cologne, DE	presentation nr 231
Edith Julia, Pierre-Bénite, FR	presentation nr 123
Mouhamad Khouja, Kiel, DE	presentation nr 114
Amira Marouf, Paris, FR	presentation nr 369
Bernard Douglas Maybury, Birmingham, GB	presentation nr 134
Patrizia Mondello, New York, NY, US	presentation nr 150
Skye Montoya, Miami, FL, US	presentation nr 403
Laura Ondrisova, Brno, CZ	presentation nr 023
Ivana Spasevska, Oslo, NO	presentation nr 013

## Scientific collaborations

The 17-ICML program will be part of the sixth edition of the Certificate of Competence in Lymphoma, a 14-month ECTS program developed by the **European School of Oncology - ESO** and academically recognized by Ulm University. The aim of the Certificate of Competence is to provide a curriculum of studies to advance the knowledge and science in the management of lymphoma patients. Further information can be obtained by visiting [www.eso.net](http://www.eso.net)

17-ICML is an European School of Oncology labelled meeting.

17-ICML is supported by the **European Society for Medical Oncology - ESMO** and is accredited with 25 ESMO-MORA cat. 1 points.

## ICML Wi-Fi

Complimentary internet wi-fi access is available for Conference delegates throughout the venue. To access wi-fi, please use the following information:  
network name (SSID): ICML2023  
password (PSK): Lugano2023  
or scan the below QRcode:



Please note that wi-fi connection speed and performance depend on number of simultaneous accesses. The live streaming of the sessions will not be displayed via the complimentary Wi-Fi network.



# 17-ICML LOCATIONS AND FLOORPLANS

1

**Palazzo dei Congressi**  
Piazza Indipendenza 4

2

**Marquee**  
Parco Ciani

3

**Villa Ciani**  
Parco Ciani

4

**Il Ciani Building**  
Via Carlo Cattaneo 5

5

**Cinema Corso**  
Via G. B. Pioda 4

6

**Auditorium**  
**West Campus USI**  
Via G. Buffi 13

7

**Polivalente room**  
**East Campus USI**  
Via La Santa 1

8

**Campo Marzio Parking**  
Via Campo Marzio



**Autosilo Via Balestra**  
Autopostale bus stop



**Lugano Centro**  
TPL line bus stop



**Lugano FFS and FLP Stations**




**Hospital EOC Ospedale**  
**Regionale di Lugano**  
- Italiano



**Parking**



Scan to get  
the map



# PALAZZO DEI CONGRESSI

## Palazzo dei Congressi

Piazza Indipendenza 4, Lugano

Scientific program, Industry program, Registration Desk, Meeting rooms C2, C3, D, E and H

Services: buvette, wi-fi, water dispensers, cloakroom, restrooms (level -1)

The following services will be available in Palazzo dei Congressi:

### 17-ICML Registration and Information Desk

Monday, June 12

only by appointments, only for groups

from Tuesday, June 13 to Friday, June 16

07:00 – 19:30

Saturday, June 17

07:00 – 13:00

### Speaker Preview Center

Monday, June 12

by appointment only

09:00 – 13:00

Monday, June 12

13:00 – 19:30

from Tuesday, June 13 to Friday, June 16

07:00 – 19:30

### Transport Info Desk (for information on public transports and 17-ICML bus services) and cloakroom

from Tuesday, June 13 to Friday, June 16

07:00 – 19:30

Saturday, June 17

07:00 – 13:00

Saturday, June 17


only for the cloakroom

07:00 – 18:00


### Amiconi Consulting SA info Desk, for information on hotel accommodation, private transfer services

Ph. +41 58 866 66 78

## First floor



## Ground floor




# IL CIANI BUILDING

## Il Ciani building

Via Carlo Cattaneo 5

Meeting rooms 11 – 17, Sit & Meet area

Services: wi-fi, water dispensers, restrooms (ground floor)



# MARQUEE

## Marquee

Parco Ciani

Poster Session, Overflow Area, Exhibition Area, Coffee and Lunch Area

Services: wi-fi, water dispenser, restrooms

### OPENING HOURS – EXHIBITION AREA

Wednesday, June 14	10:00 – 18:00
Thursday, June 15	10:00 – 18:00
Friday, June 16	10:00 – 18:00

### OPENING HOURS – OVERFLOW AREA

Wednesday, June 14	10:00 – 18:00
Thursday, June 15	09:00 – 18:00
Friday, June 16	09:00 – 18:00

### OPENING HOURS – POSTER SESSION

Wednesday, June 14	12:00 – 18:00
Thursday, June 15	09:00 – 18:00
Friday, June 16	09:00 – 18:00





# VILLA CIANI

## Villa Ciani

Parco Ciani

Meeting rooms 1 – 10, Sit & Meet area

Services: wi-fi, water dispenser, restrooms (level -1)

## OPENING HOURS


Monday, June 12 12:00 – 20:00

from Tuesday, June 13 to Friday, June 16 08:00 – 20:00


## Ground floor



## Second floor



## First floor



## OTHER 17-ICML LOCATIONS

### **Cinema Corso**

Via G. B. Pioda 4

Parallel scientific sessions

Room A overflow area

Services: wi-fi, water dispenser and restroom

### **Auditorium – West Campus USI**

Via G. Buffi 13

Parallel scientific sessions

Industry program – satellite symposia

Services: wi-fi, water dispenser and restrooms

### **Polivalente room – East Campus USI**

Via La Santa 1

Parallel scientific sessions

Services: wi-fi, water dispenser and restrooms

## ICML CLIMATE IMPACT

### **1) Climate conscious event**

17-ICML is committed to being a “climate conscious event”. To partially compensate for the CO2 emissions caused by our Conference and to combat climate change, ICML is proud to partner once again with South Pole, a leading project developer and global climate solutions provider supporting more than 700 projects aiming at reducing carbon emissions and protect biodiversity. In particular, 17-ICML will support the “Envira Amazonia Tropical Forest Conservation in Brazil” project, whose goal is to protect the rainforest from logging and encroaching cattle ranches in order to preserve the area’s rich biodiversity and mitigate the CO2 emissions. The project also promotes environmental stewardship and supports health services and educational courses for the local community.

### **2) An eco-sustainable venue**

The energy needs of Palazzo dei Congressi, the main venue of the Conference, are entirely covered by sustainable products: Biogas Basic (5% biogas) and renewable electricity (Tiacqua). Both carriers are supplied by the Lugano Industrial Companies (AIL SA).

### **3) Tap Water. It comes naturally**

The water distributed in Switzerland meets very high-quality standards. 80% of the water comes from underground sources, the rest is taken from the lakes. The establishment of groundwater protection zones makes it possible to distribute half of this water without having to treat it. Lugano’s tap water is excellent, enjoy it using the refillable water bottles are provided by 17-ICML.

### **4) Go green with Ticino Ticket!**

17-ICML strongly encourage the use of public transportation in order to reduce carbon emissions and avoid unnecessary city traffic. The free of charge “Ticino Ticket” is available at hotel check-in to all 17-ICML attendees (who have booked their accommodation in Canton Ticino) to be used to their stay on all public transport in Ticino.

### **5) Fighting food waste**

When food is produced but not consumed, this leads to unnecessary CO2-emissions, biodiversity loss and land and water consumption. 25% of the environmental impact of Swiss food system is due to food waste (i.e. avoidable food losses). This corresponds to about half the environmental impact of motorised private transport in Switzerland. In order to reduce food waste, 17-ICML leftover food will be collected by L’APE DEL CUORE, a local charity organization collecting food for needy families in Ticino.

### **6) Eco-friendly gadgets**

17-ICML choose sustainable materials for its gadgets such as recycled lanyards and reusable delegate bags.



THURSDAY, JUNE 15				
Room A, Palazzo dei Congressi	Room B, Palazzo dei Congressi	Cinema Corso	Auditorium, West USI Campus	Polivalente Room, East USI Campus
Meet the Professor REP P.W.M. Johnson (08:15 - 09:00)	Meet the Professor REP P.L. Zinzani (08:15 - 09:00)	Meet the Professor REP E. Zucca (08:15 - 09:00)	Meet the Professor T. Gross (08:15 - 09:00)	Meet the Professor REP K. Cwynarski (08:15 - 09:00)
Clinical Cases Discussion HODGKIN and T-CELL LYMPHOMAS (09:15 - 10:30)	Session 1 DISSECTING LYMPHOMAS AT THE SINGLE CELL LEVEL (09:15 - 10:30)	Clinical Cases Discussion INDOLENT NHLs and CCL (09:15 - 10:30)	Clinical Cases Discussion PAEDIATRIC LYMPHOMAS (09:15 - 10:30)	Session 2 LYMPHOMAS AFFECTING THE CNS (09:15 - 10:30)
Session 3 TREATMENT OF AGGRESSIVE LYMPHOMAS	Broadcasting of Session 3 (11:00 - 12:00)			
Lunch time & Poster viewing (12:00 - 13:00)				
G. Bonadonna Memorial Lecture (13:00 - 13:45)	Broadcasting of G. Bonadonna Memorial Lecture (13:00 - 13:45)			
Session 4 CLL AND RICHTER SYNDROME (13:45 - 15:15)	Broadcasting of Session 4 (13:45 - 15:15)		Session 5 PAEDIATRIC LYMPHOMAS (13:45 - 16:45)	Broadcasting of Session 4 (13:45 - 15:15)
Session 6 PERIPHERAL T-CELL LYMPHOMAS (15:30 - 16:45)	Session 7 NEW CAR- T CELL APPROACHES (15:30 - 16:45)	Broadcasting of Session 7 (15:30 - 16:45)		Broadcasting of Session 7 (15:30 - 16:45)
"Focus on..." session on T-CELL LYMPHOMAS (17:00 - 18:00)	"Focus on..." session on CAR - T CELL (17:00 - 18:00)	"Focus on..." session on LARGE B-CELL LYMPHOMAS (17:00 - 18:00)	"Focus on..." session on RADIOTHERAPY (17:00 - 18:00)	"Focus on..." session on LYMPHOMA MICROENVIRONMENT (17:00 - 18:00)
Industry sponsored symposium Kite, A Gilead Company (19:00 - 20:30)	Industry sponsored symposium Janssen (19:00 - 20:30)		Industry sponsored symposium Follicular Lymphoma Foundation (19:00 - 20:30)	

FRIDAY, JUNE 16				
Room A, Palazzo dei Congressi	Room B, Palazzo dei Congressi	Cinema Corso	Auditorium, West USI Campus	Polivalente Room, Est USI Campus
Meet the Professor REP M. Dreyling (08:15 - 09:00)	Meet the Professor REP S. Barrington (08:15 - 09:00)	Meet the Professor H. Beltraminelli (08:15 - 09:00)	Meet the Professor REP L. Pasqualucci (08:15 - 09:00)	Meet the Professor REP J.W. Friedberg (08:15 - 09:00)
Clinical Cases Discussion AGGRESSIVE NHLs (09:15 - 10:30)	Session 8 EPIGENETIC MECHANISMS AND TARGETED THERAPIES IN B- AND T- CELL LYMPHOMAS	Clinical Cases Discussion DIFFICULT PATHOLOGICAL CASES (09:15 - 10:30)	WORKSHOP LYMPHOMA RADIOTHERAPY organized by International Lymphoma Radiation Oncology Group - ILROG "Opportunities in Lymphoma Radiation Therapy Today: Lower Doses, Fewer Fractions, and Real World "Big Data" Analyses using Machine Learning and Artificial Intelligence" (09:00 - 12:00)	Session 9 PET IMAGING (09:15 - 10:30)
Session 10 HODGKIN LYMPHOMA (11:00 - 12:00)	Broadcasting of Session 10 HODGKIN LYMPHOMA (11:00 - 12:00)			Broadcasting of Session 10 HODGKIN LYMPHOMA (11:00 - 12:00)
Lunch time & Poster viewing (12:00 - 13:00)				
J. Ultmann Memorial Lecture (13:00 - 13:45)	Broadcasting of J. Ultmann Memorial Lecture (13:00 - 13:45)			
Session 11 MARGINAL ZONE LYMPHOMA (13:45 - 15:00)	Session 12 LYMPHOMA BIOLOGY (13:45 - 15:00)	Broadcasting of Session 11 MARGINAL ZONE LYMPHOMA (13:45 - 15:00)	IBSA FOUNDATION SPECIAL FORUM "Personalized therapy in oncology" (14:30 - 16:30)	UCLL - ICML JOINT SESSION "Lymphoma research: news from China and Europe" (14:30 - 17:15)
Closed Workshop Report	Broadcasting of Closed Workshop Report			
Session 13 FOLLICULAR LYMPHOMA (15:30 - 17:00)	Broadcasting of Session 13 (15:30 - 17:00)			
ESMO-ICML Special Lecture (17:00 - 17:30)	Broadcasting of ESMO-ICML Special Lecture (17:00 - 17:30)			
Farewell Coffee Break (17:30 - 18:00)				
THE BIG DEBATE Satellite symposium organized by the Foundation for the Institute of Oncology Research (IOR)* (18:00 - 19:00)				





# CONFERENCE SCHEDULE (updated on May 15 )

## TUESDAY, JUNE 13

<b>Polivalente room</b> East Campus USI	09:00 – 17:00	<b>CLOSED WORKSHOP</b> <b>Lugano Classification: Looking towards the future</b> Organizing Committee: Bruce D. Cheson, Bethesda, MD, US, Sally Barrington, London, GB, Andrew T. Lister, London, GB, Emanuele Zucca, Bellinzona, CH <i>organized with the support of the American Association for Cancer Research – AACR, the European School of Oncology – ESO and the European Society for Medical Oncology - ESMO</i> (by invitation only)
<b>3 parallel symposia</b>		
<b>Room A</b>	11:30 – 13:00	<b>Kite, A Gilead Company</b> <b>Improving outcomes in R/R DLBCL: Learning from challenging cases</b> Chair: Marie-José Kertsen, Amsterdam, NL
<b>Room B1</b>	11:30 – 13:00	<b>Regeneron</b> <b>Optimizing Treatment Paradigms for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) With the Emerging Class of Bispecific Antibodies</b>
<b>Room B2</b>	11:30 – 13:00	<b>Eli Lilly and Company</b> <b>Transforming Relapsed/Refractory MCL: Exploring New Options for Your Patients</b>
<b>4 parallel symposia</b>		
<b>Room A</b>	14:00 – 15:30	<b>Kite, A Gilead Company</b> <b>Evolving survival outcomes with CAR T in 2L DLBCL</b> Chair: Anna Sureda, Barcelona, ES
<b>Room B1</b>	14:00 – 15:30	<b>Novartis</b> <b>Using Real-World Experience to Optimize CAR-T Cell Therapy in Lymphoma</b> Chair: Thorsten Zenz, Zurich, CH

<b>Room B2</b>	14:00 – 15:30	<b>Incyte</b> <b>What to do when CAR Ts are not the most appropriate option in 2L DLBCL. Current treatment options for transplant-ineligible patients</b> Chair: Björn Chapuy, Berlin, DE
<b>Auditorium</b> West Campus USI	14:00 – 15:30	<b>MSD</b> <b>Aggressive B-cell lymphomas, ROR1 modalities and ADCs: Why it Matters</b> Chair: Thomas Kipps, La Jolla, CA, US
<b>Cinema Corso</b>	15:00 – 17:30	<b>LYMPHOMA RADIOTHERAPY WORKSHOP</b> <b>Radiation therapy as an immunogenic cell death mechanism in the environment of immunotherapy and adoptive cell therapy</b> Moderators: Bouthaina S. Dabaja, Houston, TX, US and Joachim Yahalom, New York, NY, US <i>organized in collaboration with the International Lymphoma Radiation Oncology Group - ILROG</i> (open to all 17-ICML attendees)
	15:00 – 15:05	<b>Past, present and future (hematology perspective)</b> Stephen Ansell, Rochester, MN, US
	15:05 – 15:25	<b>Experimental basis for the contribution of radiation therapy to CAR-T cell therapy</b> Carl DeSelm, St Louis, MO, US
	15:25 – 15:40	<b>Review of current RT/ CAR-T programs data</b> Brandon Imber, New York, NY, US
	15:40 – 16:00	<b>Break</b>
	16:00 – 16:20	<b>Is there a role for consolidation RT post-CAR-T? Patient selection and technical considerations</b> George Mikhaeel, London, UK
	16:20 – 16:40	<b>Spectrum of CAR-T and future directions</b> Bouthaina S. Dabaja, Houston, TX, US
	16:40 – 16:55	<b>Case presentation and discussion</b> Bouthaina S. Dabaja, Houston, TX, US and Timothy Robinson, New Haven, CT, US
	16:55 – 17:15	<b>Summary and Conclusions</b> Joachim Yahalom, New York, NY, US

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

Friday, June 16

Saturday, June 17

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

Friday, June 16

Saturday, June 17

4 parallel symposia		
<b>Room A</b>	16:30 – 18:00	<b>Bristol Myers Squibb</b> <b>Advances in the Management of B Cell Malignancies: Updates and Future Directions</b> Chair: Jeremy Abramson, Boston, MA, US
<b>Room B1</b>	16:30 – 18:00	<b>Genmab</b> <b>Beyond the Horizon: Perspectives on the Treatment of Later-Line Large B-Cell Lymphoma (LBCL)</b> Chair: Chan Cheah, Perth, AU
<b>Room B2</b>	16:30 – 18:00	<b>Roche</b> <b>T-cell engaging bispecific antibodies in the management of relapsed/refractory follicular lymphoma</b> Chair: Graham Collins, Oxford, GB <i>Satellite symposium abstract available in the Abstract book</i>
<b>Auditorium</b> West Campus USI	16:30 – 18:00	<b>Satellite symposium organized by PeerView, supported by AstraZeneca</b> <b>Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative Strategies</b> Chair: Martin Dreyling, Munich, DE
19:00 – 20:30 3 parallel symposia		
<b>Room A</b>	19:00 – 20:30	<b>Roche</b> <b>What does the future hold for DLBCL treatment and prognosis?</b> Chair: Franck Morschhauser, Lille, FR <i>Satellite symposium abstract available in the Abstract book</i>
<b>Room B1</b>	19:00 – 20:30	<b>Sobi</b> <b>Closing the gap: Unmet Needs and Emerging Treatments in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)</b> Chair: Georg Lenz, Münster, DE
<b>Room B2</b>	19:00 – 20:30	<b>AbbVie</b> <b>Optimizing Treatment Strategies for Patients with Chronic Lymphocytic Leukemia (CLL): An Expert Discussion</b> Chair: Thorsten Zenz, Zurich, CH

## WEDNESDAY, JUNE 14

Article nr.

“MEET THE PROFESSOR” SESSIONS		
5 parallel sessions		
<b>Room A</b>	08:30 – 09:15	<b>Update on Follicular Lymphoma</b> Jonathan W. Friedberg, Rochester, NY, US repeated on Friday, June 16, in Polivalente room
<b>Room B</b>	08:30 – 09:15	<b>Germinal center in the genesis of lymphomas</b> Laura Pasqualucci, New York, NY, US repeated on Friday, June 16, in Auditorium
<b>Cinema Corso</b>	08:30 – 09:15	<b>Are we reaching the maximum cure rate for Hodgkin lymphoma?</b> Peter W.M. Johnson, London, GB repeated on Thursday, June 15, in Room A
<b>Auditorium</b> West Campus USI	08:30 – 09:15	<b>Reappraisal of role of radiation therapy in lymphoma treatment</b> Lena Specht, Copenhagen, DK offered only once
<b>Polivalente room</b> East Campus USI	08:30 – 09:15	<b>Advances in PET and radiomics</b> Sally Barrington, London, GB repeated on Friday, June 16, in Room B
“MEET THE PROFESSOR” SESSIONS		
5 parallel sessions		
<b>Room A</b>	09:30 – 10:15	<b>Peripheral T-cell lymphomas</b> Pier Luigi Zinzani, Bologna, IT repeated on Thursday, June 15, in Room B
<b>Room B</b>	09:30 – 10:15	<b>Marginal zone lymphomas</b> Emanuele Zucca, Bellinzona, CH repeated on Thursday, June 15, in Cinema Corso
<b>Cinema Corso</b>	09:30 – 10:15	<b>Lymphoma in pregnancy</b> Fedro A. Peccatori, Milan, IT offered only once
<b>Auditorium</b> West Campus USI	09:30 – 10:15	<b>Management of Primary and Secondary CNS Lymphoma</b> Kate Cwynarski, London, GB repeated on Thursday, June 15, in Polivalente room

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

Friday, June 16

Saturday, June 17

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

Friday, June 16

Saturday, June 17

<b>Polivalente room</b> East Campus USI	09:30 – 10:15	<b>Mantle Cell lymphoma – Update on molecular biology, prognostication and treatment approaches</b> Martin Dreyling, Munich, DE repeated on Friday, June 16, in Room A	EBO4
	10:15 – 10:35	<b>Coffee break</b>	
<b>Marquee</b>	10:00 – 12:00	<b>POSTER SESSION set - up</b> <b>EDUCATIONAL SYMPOSIA</b> <b>2 parallel sessions</b>	
	10:35 – 12:00	<b>DIFFUSE LARGE B-CELL LYMPHOMAS</b> Chair: Gilles Salles, New York, NY, US	
<b>Room A,</b> broadcast in Cinema Corso	10:35 – 11:00	<b>CAR T-cell Therapy in Large B Cell Lymphoma</b> Gilles Salles, New York, NY, US	EB15
	11:00 – 11:25	<b>The evolving therapy of DLBCL: Bispecific antibodies</b> Martin Hutchings, Copenhagen, DK	EB14
	11:25 – 11:50	<b>Novel Agents in Relapsed/ Refractory Diffuse Large B-cell Lymphoma</b> Ranjana H. Advani, Stanford, CA, US	EB13
	11:50 – 12:00	<b>Discussion</b>	
	12:00 – 13:00	<b>Lunch time and Poster viewing</b>	
<b>Room B,</b> broadcast in Marquee and Polivalente room, East Campus USI	10:35 – 12:00	<b>CHRONIC LYMPHOCYTIC LEUKEMIA</b> Chair: Michael Hallek, Cologne, DE	
	10:35 – 11:00	<b>Functional consequences of inhibition of Bruton's Tyrosine kinase by ibrutinib in chronic lymphocytic leukemia</b> Nicholas Chiorazzi, Manhasset, NY, US	EB16
	11:00 – 11:25	<b>First line therapy of CLL</b> Michael Hallek, Cologne, DE	EB17
	11:25 – 11:50	<b>Therapy of relapsed disease and Richter's Syndrome</b> John F. Seymour, Melbourne, AU	EB18
	11:50 – 12:00	<b>Discussion</b>	

<b>Marquee</b>	12:00 – 18:00	<b>POSTER SESSION</b> Authors will be present in front of their posters from 12:30 to 13:00 for discussion with interested attendees on Thursday, 15 (odd-numbered posters) and Friday, 16 June (even-numbered posters).  EPIDEMIOLOGY 157 BIOLOGY 158 - 171 MICROENVIRONMENT 172 - 198 TRANSLATIONAL STUDIES, B-CELL LYMPHOMAS 199 - 216 TRANSLATIONAL STUDIES, PCTL AND cHL 217 - 226 TRANSLATIONAL STUDIES, LIQUID BIOPSY 227 - 241 IMAGING 242 - 251 HODGKIN LYMPHOMA 252 - 267 INDOLENT LYMPHOMAS 268 - 290 EXTRANODAL LYMPHOMAS NON MZL 291 - 303 DLBCL 304 - 337 CLL 338 - 345 MCL 346 - 359 PTCL 360 - 378 PLASMA CELL NEOPLASMS AND AMYLOIDOSIS 379 - 380 CAR-T (CELLULAR THERAPIES) 381 - 402 PRECLINICAL NEW DRUGS 403 - 419 PHASE I-II 420 - 451 PEDIATRIC / YOUNG ADULTS 452 - 455 INFECTIONS 456 - 458	
	13:00 – 13:55	<b>OPENING OF THE CONFERENCE</b> <b>WELCOME AND INTRODUCTORY REMARKS</b> F. Cavalli, Bellinzona, CH  <b>HENRY KAPLAN MEMORIAL LECTURE AND SAN SALVATORE FOUNDATION PRIZE</b> Introduction to San Salvatore Foundation: Stefano Coduri, Lugano, CH  Laudatio: Rolf Stahel, Zurich, CH  <b>Lessons Learned from the Genetic Heterogeneity of Lymphoid Malignancies</b> Margaret A. Shipp, Boston, MA, US	001
<b>Room A,</b> broadcast in all rooms			

14:00 – 15:15	<b>PLENARY SESSION</b> Chairs: Franco Cavalli, Bellinzona, CH and Catherine Thieblemont, Paris, FR	
14:00 – 14:15	<b>Frontline intensified ABVD demonstrates superior efficacy than PET-adapted ABVD in advanced Hodgkin Lymphoma: the FIL-Rouge Phase 3 Trial by the Fondazione Italiana Linfomi</b> Antonio Pinto, Naples, IT	004
14:15 – 14:30	<b>Nivolumab(N)-AVD Improves Progression-Free Survival Compared to Brentuximab Vedotin (BV)-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL): Results of SWOG S1826</b> Alex F. Herrera, Duarte, CA, US	005
14:30 – 14:45	<b>Discussant</b> Peter Borchmann, Cologne, DE	
14:45 – 15:00	<b>Fourth generation huCART19-IL18 produces durable responses in lymphoma patients previously relapsed/refractory to anti-CD19 CAR T-cell therapy</b> Jakub Svoboda, Philadelphia, PA, US	006
15:00 – 15:15	<b>Discussant</b> Gilles Salles, New York, NY, US	
<b>Marquee</b>	<b>15:15 – 15:45 Coffe break</b>	
<b>Room A, broadcast in all rooms</b>	<b>15:45 – 16:45 AACR – ICML JOINT SESSION Technology that will change lymphoma understanding and care</b> Chairs: Francesco Bertoni, Bellinzona, CH and Margaret Foti, Philadelphia, PA, US	
15:45 – 16:05	<b>Single cell omics in the study of B cell lymphoma</b> Katia Basso, New York, NY, US	007
16:05 – 16:25	<b>Circulating tumor DNA (liquid biopsy)</b> Davide Rossi, Bellinzona, CH	008
16:25 – 16:45	<b>Organoids</b> Arianna Baggiolini, Bellinzona, CH	009

## “FOCUS ON...” SESSIONS

### 5 parallel sessions

<b>Room A</b>	17:00 – 18:00	<b>Mantle Cell Lymphoma</b> Chairs: Martin Dreyling, Munich, DE and John P. Leonard, New York, NY, US	
	17:00 – 17:10	<b>Five-year update of the first-line IMCL-2015 GELTAMO study. Prolonged molecular and clinical responses were observed after MRD-driven ibrutinib discontinuation</b> Eva Giné, Barcelona, ES	098
	17:10 – 17:20	<b>Acalabrutinib with rituximab as first-line therapy for older patients with mantle cell lymphoma – a phase II clinical trial</b> Preetesh Jain, Houston, TX, US	099
	17:20 – 17:30	<b>Very Long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.</b> Clémentine Sarkozy, Saint Cloud, FR	100
	17:30 – 17:40	<b>Ibrutinib-rituximab and venetoclax (IRV) followed by risk-stratified R-HyperCVAD/MTX in young patients with untreated mantle cell lymphoma – phase-II WINDOW-2 trial</b> Michael L. Wang, Houston, TX, US	101
	17:40 – 17:50	<b>Pirtobrutinib in covalent BTK-inhibitor pre-treated mantle cell lymphoma: updated results, subgroup analysis from BRUIN with &gt;3 years follow-up from start of enrollment</b> Chan Y. Cheah, Perth, AU	102
	17:50 – 18:00	<b>Outcomes of autologous transplant, allogeneic transplant, and CAR T cell therapy in TP53 altered mantle cell lymphoma: a multi-institution retrospective analysis</b> Marcus Messmer, Philadelphia, PA, US	103

<b>Room B,</b> broadcast in Marquee	17:00 – 18:00	<b>Hodgkin Lymphoma</b> Chairs: Ranjana H. Advani, Stanford, CA, US and Peter Borchmann, Cologne, DE	
	17:00 – 17:10	<b>Correlation between progression-free and overall survival in patients with classical Hodgkin lymphoma: a comprehensive analysis of individual patient data from GHSG trials</b> Paul J. Bröckelmann, Cologne, DE	104
	17:10 – 17:20	<b>Early FDG-PET adapted treatment of limited stage Hodgkin lymphoma (HL): 10y long term follow-up analysis of the randomized Intergroup EORTC/LYSA/FIL H10 trial</b> Massimo Federico, Modena, IT	105
	17:20 – 17:30	<b>Pembrolizumab as first therapy for Hodgkin lymphoma is deliverable in older or ABVD-ineligible patients, allows subsequent therapy, and gives adequate survival</b> Michael J. Dickinson, Melbourne, AU	106
	17:30 – 17:40	<b>Phase 2 trial of Nivolumab plus Adriamycin, Vinblastine, Dacarbazine (N-AVD) as Frontline Therapy in Older Adults with Hodgkin Lymphoma</b> Pallawi Torka, New York, NY, US	107
	17:40 – 17:50	<b>Avelumab monotherapy followed by a PET adapted chemotherapy approach in the first line treatment of classical Hodgkin Lymphoma: Initial results from the AVeNuE window study</b> Graham P. Collins, Oxford, GB	108
	17:50 – 18:00	<b>Favezelimab plus pembrolizumab in anti-PD-1-refractory classical Hodgkin lymphoma (cHL): Estimating the relative efficacy of favezelimab</b> Philippe Armand, Boston, MA, US	109
	<b>Cinema Corso</b>	17:00 – 18:00	<b>Ongoing trials</b> Chairs: John Kuruvilla, Toronto, ON, CA and Grzegorz S. Nowakowski, Rochester, NJ, US
	17:00 – 17:10	<b>SAKK 38/19: Assessing a ctDNA and PET-oriented therapy in patients with DLBCL. A multicenter, open-label, phase II trial.</b> Anastasios Stathis, Bellinzona, CH	OT1
	17:10 – 17:20	<b>REMoDL-A: A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma (DLBCL) with Acalabrutinib</b> Vivek S. Radhakrishnan, Southampton, GB	OT2
	17:20 – 17:30	<b>Brentuximab Vedotin-Nivolumab alone and then with Rituximab-Cyclophosphamide-Doxorubicin-Prednisone as Frontline Therapy of Primary Mediastinal Large B-cell Lymphoma</b> Raphael E. Steiner, Houston, TX, US	OT3
	17:30 – 17:40	<b>MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 versus lenalidomide plus rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma</b> Laurie H. Sehn, Vancouver, BC, CA	OT4
	17:40 – 17:50	<b>SUNMO: Phase III trial of mosunetuzumab plus polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in relapsed/refractory aggressive non-Hodgkin lymphoma</b> Astrid Pavlovsky, Buenos Aires, AR	OT5
	17:50 – 18:00	<b>ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucef vs Standard of Care as First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma</b> Jason R. Westin, Houston, TX, US	OT6
<b>Auditorium</b> West Campus USI	17:00 – 18:00	<b>Liquid Biopsy and Minimal Residual Disease</b> Chairs: Christiane Pott, Kiel, DE and Davide Rossi, Bellinzona, CH	
	17:00	<b>Molecular clustering on ctDNA improves the prognostic stratification of DLBCL patients compared to ctDNA levels</b> Riccardo Moia, Novara, IT	110



17:10	<b>Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study</b> Alex F. Herrera, Duarte, CA, US	111	
17:20	<b>MRD-Negativity After Frontline DLBCL Therapy: Pooled Analysis of 6 Clinical Trials</b> Mark Roschewski, Bethesda, MD, US	112	
17:30	<b>Early ctDNA clearance after CAR T-cell infusion predicts outcome in patients with Large B-cell lymphoma: results from ALYCANTE, a phase 2 LYSA study</b> Marie-Hélène Delfau-Larue, Creteil, FR	113	
17:40	<b>Cell-free DNA kinetics decipher potential mechanisms of action of Ibrutinib combination therapy in mantle cell lymphoma (MCL)</b> Mouhamad Khouja, Kiel, DE	114	
17:50	<b>Combined use of minimal residual disease monitoring and FDG-PET for outcome prediction in follicular lymphoma: results from the Fondazione Italiana Linfomi (FIL) FOLL12 trial</b> Simone Ferrero, Turin, IT	115	
<b>Polivalente room</b> East Campus USI	17:00 – 18:00	<b>Mechanisms of treatment resistance</b> Chairs: Vincent Ribrag, Villejuif, FR and Patrizia Mondello, Rochester, MN, US	
	17:00 – 17:10	<b>Genomic evolution and resistance to pirtobrutinib in covalent BTK-inhibitor pre-treated chronic lymphocytic leukemia patients: results from the phase I/II BRUIN study</b> Krish Patel, Seattle, WA, US	116
	17:10 – 17:20	<b>Single-cell RNA-Seq of classic hairy cell leukemia reveals disease drivers linked to intrinsic treatment resistance and identifies DUSP1 as potential new therapeutic target</b> Jan-Paul Bohn, Innsbruck, AT	117

17:20 – 17:30	<b>IL16 production is a mechanism of resistance to BTK inhibitors and to R-CHOP</b> Alberto Arribas, Bellinzona, CH	118
17:30 – 17:40	<b>Enhancer RNAs (eRNAs) play a role in the response to small molecules and in the development of acquired resistance in marginal zone lymphoma (MZL).</b> Sara Napoli, Bellinzona, CH	119
17:40 – 17:50	<b>Harnessing BTKi therapy by CDK4/6i control of T cell surveillance</b> Selina Chen-Kiang, New York, NY, US	120
17:50 – 18:00	<b>Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma</b> Preetesh Jain, Houston, TX, US	121

### 3 parallel symposia

<b>Room A</b>	19:00 – 20:30	<b>AbbVie</b> <b>Navigating the Rapidly Changing Treatment Landscape in DLBCL</b> Chair: Georg Lenz, Münster, DE
<b>Room B</b>	19:00 – 20:30	<b>Takeda</b> <b>The future of therapy for CD30+ lymphomas: addressing challenges and driving progress</b> Chair: Anna Sureda, Barcelona, ES
<b>Auditorium</b> West Campus USI	19:00 – 20:30	<b>BeiGene</b> <b>Targeting BTK across B-Cell Malignancies – Selecting the right treatment for patients with lymphoma or CLL</b> Chair: Stephen Stilgenbauer, Ulm, DE

## THURSDAY, JUNE 15

### “MEET THE PROFESSOR” SESSIONS

#### 5 parallel sessions

<b>Room A</b>	08:15 – 09:00	<b>Are we reaching the maximum cure rate for Hodgkin lymphoma?</b> Peter W.M. Johnson, London, GB repetition	EB07
---------------	---------------	---	------

<b>Room B</b>	08:15 – 09:00	<b>Peripheral T-cell lymphomas</b> Pier Luigi Zinzani, Bologna, IT repetition	EB11
<b>Cinema Corso</b>	08:15 – 09:00	<b>Marginal zone lymphomas</b> Emanuele Zucca, Bellinzona, CH repetition	EB12
<b>Auditorium</b> West Campus USI	08:15 – 09:00	<b>Post-Transplant Lymphoproliferative Disease (PTLD) in Children, Adolescents, and Young Adults</b> Thomas Gross, Aurora, CO, US offered only once	EB06
<b>Polivalente room</b> East Campus USI	08:15 – 09:00	<b>Management of Primary and Secondary CNS Lymphoma</b> Kate Cwynarski, London, GB repetition	EB03
<b>Marquee</b>	09:00 – 18:00	<b>POSTER SESSION</b>  <b>“CLINICAL CASES DISCUSSION” SESSIONS</b>  <b>3 parallel sessions</b>	
<b>Room A</b>	09:15 – 10:30	<b>HODGKIN AND T-CELL LYMPHOMAS</b> Chair: Andrew T. Lister, London, UK Presenter: Alden Moccia, Bellinzona, CH Discussants: Richard Hoppe, Stanford, CA, US, Andrew T. Lister, London, UK and Astrid Pavlovsky, Buenos Aires, AR	
<b>Cinema Corso</b>	09:15 – 10:30	<b>INDOLENT NHLs AND CLL</b> Chair: Jonathan Friedberg, Rochester, NY, US Presenter: Adalgisa Condoluci, Bellinzona, CH Discussants: Jonathan Friedberg, Rochester, NY, US, Mary Gospodarowicz, Toronto, ON, CA and Michael Hallek, Cologne, DE	
<b>Auditorium</b> West Campus USI	09:15 – 10:30	<b>PEDIATRIC LYMPHOMAS</b> Chair: Wilhelm Wössmann, Hamburg, DE Presenter: Francesco Ceppi, Lausanne, CH Discussant: Thomas Gross, Aurora, CO, US	
<b>Room B,</b> broadcast in Marquee	09:15 – 10:30	<b>SESSION 1 - DISSECTING LYMPHOMAS AT THE SINGLE CELL LEVEL</b> Chair: Elias Campo, Barcelona, ES and Leticia Quintanilla de Fend, Tübingen, DE	

	09:15 – 09:35	<b>The tumor microenvironment of Hodgkin lymphoma at single cell resolution</b> Christian Steidl, Vancouver, B.D., CA	010
	09:35 – 09:55	<b>Trajectories of lymphomagenesis</b> Bertrand Nadel, Marseille, FR	011
	09:55 – 10:15	<b>Subclonal heterogeneity driving progression and transformation in chronic lymphocytic leukemia</b> Elias Campo, Barcelona, ES	012
	10:15 – 10:30	<b>Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma</b> Ivana Spasevska, Oslo, NO	013
<b>Polivalente room</b> East Campus USI	09:15 – 10:30	<b>SESSION 2 - LYMPHOMAS AFFECTING THE CNS</b> Chairs: Kate Cwynarski, London, GB and Andrés J. Ferreri, Milan, IT  <b>5 parallel sessions</b>	
	09:15 – 09:30	<b>Identification of Genomic Biomarkers of Disease Progression and Survival in Newly-Diagnosed Primary CNS Lymphoma</b> James Rubenstein, San Francisco, CA, US	014
	09:30 – 09:45	<b>Consolidative HCT-ASCT is superior to non-myeloablative chemo-immunotherapy in newly-diagnosed PCNSL - Updated results of the randomized phase III MATRix/IELSG43 trial</b> Gerard Illerhaus, Stuttgart, DE	015
	09:45 – 10:00	<b>CAR-T cells radically modify the management of relapsed/refractory primary cerebral lymphomas. Real life results of the French LOC network</b> Sylvain Choquet, Paris, FR	016
	10:00 – 10:15	<b>Phase 2 study of ibrutinib with temozolomide, etoposide, liposomal doxorubicin, dexamethasone, rituximab (TEDDi-R) for secondary CNS lymphoma</b> Mark Roschewski, Bethesda, MD, US	017

Tuesday, June 13

Wednesday, June 14

**Thursday, June 15**

Friday, June 16

Saturday, June 17

Tuesday, June 13

Wednesday, June 14

**Thursday, June 15**

Friday, June 16

Saturday, June 17

	10:15 – 10:30	<b>Five-year results of a phase 2 study of CNS-oriented therapy with R-CHOP for untreated intravascular large B-cell lymphoma: Final analysis of the PRIMEUR-IVL study</b> Kazuyuki Shimada, Nagoya, JP	018
<b>Marquee</b>	10:30 – 11:00	<b>Coffee break</b>	
<b>Room A,</b> broadcast in all rooms	11:00 – 12:00	<b>SESSION 3 - TREATMENT OF AGGRESSIVE LYMPHOMAS</b> Chair: Franck Morschhauser, Lille, FR and Laurie H. Sehn, Vancouver, BC, CA	
	11:00 – 11:15	<b>A randomized trial of observation versus radiotherapy in primary mediastinal B-cell lymphoma patients with complete metabolic response after standard immunochemotherapy.</b> Andrew J. Davies, Southampton, GB	019
	11:15 – 11:30	<b>R-CODOX-M/R-IVAC versus DA-EPOCH-R in Patients with newly diagnosed high-risk Burkitt lymphoma: Final results of a multi-center randomized HOVON/SAKK trial.</b> Martine Chamuleau, Amsterdam, NL	020
	11:30 – 11:45	<b>Biomarker-driven treatment strategy in high-risk large B-cell lymphoma (NLG-LBC-06 phase II trial): Impact of ctDNA and TP53 aberrations on clinical outcome</b> Sirpa Leppä, Helsinki, FI	021
	11:45 – 12:00	<b>Primary overall survival analysis of the Phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard of care in relapsed/refractory large B cell lymphoma</b> Jason R. Westin, Houston, TX, US	022
<b>Marquee</b>	12:00 – 13:00	<b>Lunch time and Poster viewing</b>	

<b>Room A,</b> broadcast in all rooms	13:00 – 13:45	<b>GIANNI BONADONNA MEMORIAL LECTURE</b> Supported by the European School of Oncology – ESO  Laudatio : Riccardo Dalla-Favera, New York, NY, US  <b>Elucidating the enigmatic pathobiology of Hodgkin lymphoma</b> Ralf Küppers, Essen, DE	002
<b>Room A,</b> broadcast in room B, Marquee, Cinema Corso and Polivalente room, East Campus USI	13:45 – 15:15	<b>SESSION 4 - CLL AND RICHTER SYNDROME</b> Chairs: Michael J. Hallek, Cologne, DE and Thorsten Zenz, Zurich, CH	
	13:45 – 14:00	<b>FoxO1-Rictor axis induces Akt phosphorylation during CLL cell adaptation to BCR inhibitors: implications for combinatorial therapy</b> Laura Ondrisova, Brno, CZ	023
	14:00 – 14:15	<b>Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): Final results of the CLL12 trial</b> Petra Langerbeins, Cologne, DE	024
	14:15 – 14:30	<b>Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study</b> Othman Al-Sawaf, Cologne, DE	025
	14:30 – 14:45	<b>Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004</b> Tanya Siddiqi, Duarte, CA, US	026
	14:45 – 15:00	<b>Efficacy and safety of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter Syndrome</b> Anna M. Frustaci, Milan, IT	027
	15:00 – 15:15	<b>Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter's transformation</b> Carmelo Carlo-Stella, Milan, IT	028

<b>Auditorium</b> West Campus USI	13:45 – 16:45	<b>SESSION 5 - PEDIATRIC LYMPHOMAS</b> Chair: Francesco Ceppi, Lausanne, CH	
	13:45 – 14:10	<b>Primary mediastinal B cell lymphoma in children, adolescents and young adults</b> Lisa Giulino Roth, New York, NY, US	029
	14:10 – 14:35	<b>Minimal disseminated and residual disease in pediatric NHL</b> Wilhelm Wössmann, Hamburg, DE	030
	14:35 – 14:50	<b>Phase 2 KEYNOTE-667: Pembrolizumab in children and young adults with classical Hodgkin lymphoma (cHL) with slow early response to front-line chemotherapy</b> Luciana Vinti, Rome, IT	031
	14:50 – 15:05	<b>Analysis treatment outcome of 46 refractory/relapsed pediatric mature B cell lymphoma patients-multi- center experience from China</b> Yonghong Zhang, Beijing, CN	032
	15:05 – 15:20	<b>Allogeneic hematopoietic stem cell transplantation with reduced-toxicity conditioning for pediatric relapsed or refractory ALK-positive anaplastic large cell lymphoma</b> Fabian Knörr, Hamburg, DE	033
	15:20 – 15:35	<b>Patterns of presentation and outcomes in Stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial</b> Dana Casey, Chapel Hill, NC, US	034
	15:35 – 15:45	<b>Break</b>	
	15:45 – 15:57	<b>Landscape of driver mutations and their clinical impacts in Chinese pediatric patients with mature B-cell non-Hodgkin's lymphoma and T-cell lymphoblastic lymphoma</b> Qinlong Zheng, Beijing, CN	035
	15:57 – 16:09	<b>ALK-positive anaplastic large cell lymphoma with variant ALK-fusion partner: a population-based analyses of the NHL-BFM study group</b> Christine Damm-Welk, Hamburg, DE	036

	16:09 – 16:21	<b>Lung staging in pediatric Hodgkin Lymphoma: Staging Evaluation &amp; Response Criteria Harmonization for Childhood, Adolescent &amp; Young Adult HL (SEARCH for CAYAH) consensus (432)</b> Jennifer Seelisch, London, CA	037
	16:21 – 16:33	<b>Quality of Life in Pediatric High-Risk Hodgkin Lymphoma Treated with Brentuximab-Based Intensive Chemotherapy—Comparison to Historical Treatment Cohort and Healthy Peers</b> Angela M. Feraco, Boston, MA, US	038
	16:33 – 16:45	<b>Quantitative whole-body MRI for predicting treatment outcome in pediatric patients with aggressive non-Hodgkin lymphoma undergoing chimeric antigen receptor T cell therapy</b> Yu Xia Li, Weihui, CN	039
<b>Marquee</b>	15:15 – 15:30	<b>Coffee break</b>	
<b>Room A,</b> broadcast in Cinema Corso	15:30 – 16:45	<b>SESSION 6 - PERIPHERAL T-CELL LYMPHOMAS</b> Chairs : Julie Vose, Omaha, NE, US and Pier Luigi Zinzani, Bologna, IT	
	15:30 – 15:45	<b>The genetic subtypes and the tumor microenvironment signatures are associated with distinct outcomes in peripheral T-cell lymphoma</b> Yasuhito Suehara, Tsukuba, JP	040
	15:45 – 16:00	<b>Romidepsin plus CHOP versus CHOP in Patients with Previously Untreated Peripheral T-Cell Lymphoma: final analysis of the Ro-CHOP trial</b> Vincent Camus, Rouen, FR	041
	16:00 – 16:15	<b>Targeted agents combined with CHOP compared with CHOP as the first-line therapy for peripheral T-cell lymphoma: preliminary results from a phase 2 GUIDANCE-03 Trial</b> Weili Zhao, Shanghai, CN	042
	16:15 – 16:30	<b>Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Primary Analysis of the Multinational Pivotal Study Results (JACKPOT8)</b> Won Seog Kim, Seoul, KR	043

Tuesday, June 13

Wednesday, June 14

**Thursday, June 15**

Friday, June 16

Saturday, June 17

Tuesday, June 13

Wednesday, June 14

**Thursday, June 15**

Friday, June 16

Saturday, June 17

	16:30 – 16:45	<b>First in human study of AUTO4, a TRBC1-tragetting CART T cell therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-cell Lymphoma</b> Kate Cwynarski, London, GB	044
<b>Room B,</b> broadcast in Marquee and Polivalente room, East Campus USI	15:30 – 16:45	<b>SESSION 7 - NEW CAR-T CELL APPROACHES</b> Chairs: Elise A. Chong, Philadelphia, PA, US and Anna Sureda, Barcelona, ES	
	15:30 – 15:45	<b>Phase 2 Study of Anbal-cel, Novel Anti-CD19 CAR-T therapy with Dual Silencing of PD-1 and TIGIT in Relapsed or Refractory Large B Cell Lymphoma - Interim Analysis Result</b> Won Seog Kim, Seoul, KR	045
	15:45 – 16:00	<b>Point-of-care anti-BCMA CAR T-cell therapy induces encouraging response rates in high-risk relapsed/refractory multiple myeloma</b> Hila Magen, Tel Hashomer, IL	046
	16:00 – 16:15	<b>Off-the-shelf CD30.CAR-modified Epstein-Barr Virus-specific T cells (CD30.CAR EBVSTs) provide a safe and effective therapy for patients with Hodgkin lymphoma (HL)</b> Carlos A. Ramos, Houston, TX, US	047
	16:15 – 16:30	<b>Durables responses with anti-CD19 allogeneic CAR T ALLO-501/501A in phase 1 trials of relapsed/refractory large B-cell lymphoma (r/r LBCL)</b> Frederick L. Locke, Tampa, FL, US	048
	16:30 – 16:45	<b>High efficacy and favorable safety of 3rd generation CD20 CAR-T (MB-106) for outpatient treatment of follicular lymphoma (FL) – results of a single-institution trial</b> Mazyar Shadman, Seattle, WA, US	049

**“FOCUS ON...” SESSIONS**

**5 parallel sessions**

<b>Room A</b>	17:00 – 18:00	<b>T-Cell Lymphomas</b> Chairs: Stefano Luminari, Reggio Emilia, IT and Won Seog Kim, Seoul, KR
---------------	---------------	--

	17:00 – 17:10	<b>Lack of SMARCB1 expression characterizes a subset of peripheral T-cell lymphomas enriched in children and young adults</b> Anja Fischer, Ulm, DE	122
	17:10 – 17:20	<b>Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas</b> Edith Julia, Lyon, FR	123
	17:20 – 17:30	<b>BRCA1/2 mutations impact on the development of breast implant-associated lymphoma (BIA-ALCL) in women with breast cancer reconstructed with textured breast implants.</b> Paola Ghione, New York, NY, US	124
	17:30 – 17:40	<b>A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia/lymphoma.</b> Atae Utsunomiya, Kagoshima, JP	125
	17:40 – 17:50	<b>AFM13 in patients with CD30 positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL): Results from the Phase 2 REDIRECT study</b> Won Seog Kim, Seoul, KR	126
	17:50 – 18:00	<b>Lacutamab in patients with advanced mycosis fungoides (MF): efficacy results according to updated lymph node (LN) classification in the TELLOMAK study</b> Pierluigi Porcu, Philadelphia, PA, US	127

<b>Room B,</b> broadcast in Marquee	17:00 – 18:00	<b>CAR-T Cell</b> Chairs: Tanya Siddiqi, Duarte, CA, US and Jason R. Westin, Houston, TX, US
---	---------------	---

	17:00 – 17:10	<b>Proteomic profiling identifies granzyme B inhibitor Serpin B9 as mediator of resistance to CAR T-cell and bispecific antibody treatment in nodal B-cell lymphoma</b> Berit J. Brinkmann, Heidelberg, DE	128
--	---------------	---	-----



17:10 – 17:20	<b>CART-SIE real life study: primary mediastinal B-cell lymphoma (PMBCL) have a superior outcome compared to large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel</b> Annalisa Chiappella, Milan, IT	129
17:20 – 17:30	<b>Impact of response to systemic bridging therapy on clinical outcomes and cytokine profile in patients receiving CAR T-cell therapy for aggressive B-cell lymphoma</b> Beatriz Wills, New York, NY, US	130
17:30 – 17:40	<b>Bendamustine lymphodepletion triggers reduced inflammatory cytokines and decreased toxicities after both 4-1BB- and CD28-costimulated CART19 for non-Hodgkin lymphoma</b> Guido Ghilardi, Philadelphia, PA, US	131
17:40 – 17:50	<b>Prognostic scoring systems for severe CRS and ICANS after autologous anti-CD19 CAR T cells in large B-cell lymphoma: a DESCAR-T registry study form the LYSA</b> Pierre Sesques, Pierre Benite, FR	132
17:50 – 18:00	<b>Severe hematological toxicity following CD19 CAR-T for relapsed/refractory LBCL is associated with suppressive immune dysregulation and limited CAR-T expansion</b> Kai Rejeski, Munich, DE	133
<b>Cinema Corso</b> 17:00 – 18:00	<b>Large B-Cell and Double Hit Lymphomas</b> Chairs: Andrew J. Davies, Southampton, GB and Brad Kahl, Saint Louis, MO, US	
17:00 – 17:10	<b>MYC/BCL6 double hit lymphoma negative for t(3;8) BCL6::MYC fusion is associated with inferior survival, in contrast with t(3;8) positive pseudo-double hit lymphoma</b> Bernard D. Maybury, Birmingham, GB	134

17:10 – 17:20	<b>High complete metabolic response rates with epcoritamab + R-CHOP in previously untreated (1L) high-risk DLBCL, including double-hit/triple-hit: EPCORE NHL-2 update</b> Lorenzo Falchi, New York, NY, US	135
17:20 – 17:30	<b>waveLINE-004: open-label, phase 2 study of zilovetamab vedotin (MK-2140) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)</b> Alexander Fosså, Oslo, NO	136
17:30 – 17:40	<b>Long-term responses with loncastuximab tesirine: updated results from LOTIS-2, the pivotal phase 2 study in patients with relapsed/refractory diffuse large b-cell lymphoma</b> Paolo F. Caimi, Cleveland, OH, US	137
17:40 – 17:50	<b>Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line therapy in large B-cell lymphoma (TRANSFORM study): Subgroup analyses by prior therapy response</b> Loretta J. Nastoupil, Houston, TX, US	138
17:50 – 18:00	<b>Comparative accuracy of alternative early measures of residual disease after CAR19 therapy of relapsed/refractory LBCL</b> Brian J. Sworder, Palo Alto, CA, US	139
<b>Auditorium</b> 17:00 – 18:00	<b>Radiotherapy</b> West Campus USI Chairs: Bouthaina S. Dabaja, Houston, TX and Lena Specht, Copenhagen, DK	
17:00 – 17:10	<b>Rituximab-Containing Combined Modality Therapy in Limited Stage Follicular Lymphoma: Mature follow up and derivation of a novel prognostic score from the TROG99.03 Trial</b> Michael MacManus, Brisbane, AU	140
17:10 – 17:20	<b>Radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR-T – The UK experience</b> Andrea Kuhn, London, GB	141

	17:20 – 17:30	<b>High rate of metabolic complete response after low dose radiotherapy and Obinutuzumab in early stage follicular lymphoma: Initial results of the GAZAI study (GLA 2018-3)</b> Klaus Herfarth, Heidelberg, DE	142
	17:30 – 17:40	<b>Very low dose Radiation therapy for Indolent lymphoma: Comparing “Big Boom” (4Gy x 1) versus “Boom Boom” (2Gy x 2)</b> Joachim Yahalom, New York, NY, US	143
	17:40 – 17:50	<b>Salvage Radiotherapy in Relapsed/Refractory Large B-Cell Lymphoma After CAR T-Cell Therapy Failure</b> Chirayu Patel, Boston, MA, US	144
	17:50 – 18:00	<b>Bone marrow volume irradiated and risk of cytopenias in aggressive B-cell lymphoma patients bridged with radiation therapy for CART cell therapy</b> Bouthaina S. Dabaja, Houston, TX	145
<b>Polivalente room</b> East Campus USI	17:00 – 18:00	<b>Lymphoma microenvironment</b> Chairs: Nicholas Chiorazzi, Manhasset, NY, US and Laurence L. de Leval, Lausanne, CH	
	17:00 – 17:10	<b>Immune contexture analysis in POLARIX suggests response to Pola-R-CHP treatment reduces tumor microenvironment dependency</b> Franck Morschhauser, Lille, FR	146
	17:10 – 17:20	<b>Spatially-resolved transcriptomics define clinically relevant subsets of macrophages in diffuse large B-cell lymphoma</b> Anand D. Jeyasekharan, Singapore, SG	147
	17:20 – 17:30	<b>Coordinated changes in the tumor microenvironment (TME) are associated with increased risk of therapeutic failure in newly diagnosed diffuse large B-cell lymphoma (DLBCL)</b> José C. Villasboas, Rochester, MN, US	148

	17:30 – 17:40	<b>EZH2 inhibition enhances CAR T antitumor effect by inducing lymphoma immunogenicity and enhancing T cell function</b> Wendy Béguelin, New York, NY, US	149
	17:40 – 17:50	<b>Single cell analysis reveals immune dysfunction in large B cell Lymphoma (LBCL) pts with hypomagnesemia receiving Axi-cel: results from ZUMA-1 trial and Mayo Clinic cohort</b> Patrizia Mondello, Rochester, MN, US	150
	17:50 – 18:00	<b>Follicular lymphoma patient-derived organoids for bispecific T-cell engager immunotherapy</b> Joseph G. Schroers-Martin, Stanford, CA, US	151

### 3 parallel symposia

<b>Room A</b>	19:00 – 20:30	<b>Kite, A Gilead Company</b> <b>How do we improve outcomes for underserved populations with B-cell malignancies?</b> Chair: Davide Rossi, Bellinzona, CH
<b>Room B</b>	19:00 – 20:30	<b>Janssen</b> <b>Optimizing treatment for patients with CLL and MCL now and in the future</b> Chair: John Gribben, London, GB
<b>Auditorium</b> West Campus USI	19:00 – 20:30	<b>Follicular Lymphoma Foundation</b> <b>What will it take to cure Follicular Lymphoma?</b> Chair: Mitchell Smith, CMO at the FLF, London, GB

## FRIDAY, JUNE 16

### “MEET THE PROFESSOR” SESSION

#### 5 parallel sessions

<b>Room A</b>	08:15 – 09:00	<b>Mantle Cell lymphoma – Update on molecular biology, prognostication and treatment approaches</b> Martin Dreyling, Munich, DE repetition	EB04
<b>Room B</b>	08:15 – 09:00	<b>Advances in PET and radiomics</b> Sally Barrington, London, GB repetition	EB01

Tuesday, June 13

Wednesday, June 14

**Thursday, June 15**

Friday, June 16

Saturday, June 17

Tuesday, June 13

Wednesday, June 14

**Thursday, June 15**

**Friday, June 16**

Saturday, June 17

<b>Cinema Corso</b>	08:15 – 09:00	<b>Cutaneous T-cell lymphomas – focus on some problems and some solutions</b> Helmut Beltraminelli, Locarno, CH offered only once	EB02
<b>Auditorium</b> West Campus USI	08:15 – 09:00	<b>Germinal center in the genesis of lymphomas</b> Laura Pasqualucci, New York, NY, US repetition	EB08
<b>Polivalente room</b> East Campus USI	08:15 – 09:00	<b>Update on Follicular Lymphoma</b> Jonathan W. Friedberg, Rochester, NY, US repetition	EB05
<b>Marquee</b>	09:00 – 18:00	<b>POSTER SESSION</b>	
<b>Auditorium</b> West Campus USI	09:00 – 12:00	<b>LYMPHOMA RADIOTHERAPY WORKSHOP</b> <b>Opportunities in Lymphoma Radiation Therapy Today: Lower Doses, Fewer Fractions, and Real World “Big Data” Analyses using Machine Learning and Artificial Intelligence</b> Moderators: Lena Specht, Copenhagen, DK and Mary Gospodarowicz, Toronto, ON, CA <i>organized in collaboration with the International Lymphoma Radiation Oncology Group - ILROG</i> (open to all 17-ICML attendees)	
	09:00 – 09:30	<b>Background for lower and ultra-low radiation doses for lymphoma</b> Andrea Ng, Boston, Massachusetts, US	
	09:30 – 09:50	<b>Clinical Experience with ultra-low dose regimens in indolent lymphomas – lessons from the COVID experience</b> Joanna Yang, St. Louis, MO, US	
	09:50 – 10:20	<b>Background for fewer but larger fractions (hypofractionation)</b> Umberto Ricardi, Turin, IT	
	10:20 – 10:40	<b>Clinical experience with hypofractionation – lessons from the COVID experience</b> Joanna Yang, St. Louis, MO, US	
	10:40 – 12:00	<b>Real world “Big Data” analyses to discover what really works</b> Lena Specht, Copenhagen, DK	

## “CLINICAL CASES DISCUSSION” SESSIONS

### 2 parallel sessions

<b>Room A</b>	09:15 – 10:30	<b>AGGRESSIVE NHLs</b> Chair: John P. Leonard, New York, NY, US Presenter: Maria Cristina Piroso, Bellinzona, CH Discussants: Brad Kahl, Saint Louis, MO, US and John P. Leonard, New York, NY, US	
<b>Cinema Corso</b>	09:15 – 10:30	<b>DIFFICULT PATHOLOGICAL CASES</b> Chair: Luca Mazzucchelli, Locarno, CH Presenters: Luca Mazzucchelli, Locarno, CH and Emanuele Zucca, Bellinzona, CH Discussants: Stephan Dirnhofer, Basel, CH and Leticia Quintanilla de Fend, Tuebingen, DE	
<b>Room B,</b> broadcast in Marquee	09:15 – 10:30	<b>SESSION 8 - EPIGENETIC MECHANISMS AND TARGETED THERAPIES IN B- AND T-CELL LYMPHOMAS</b> Chairs: Ari M. Melnick, New York, NY, US and Margaret A. Shipp, Boston, MA, US	
	09:15 – 09:35	<b>Epigenetic basis and therapy of DLBCL</b> Ari M. Melnick, New York, NY, US	050
	09:35 – 09:55	<b>Epigenetic regulation of immune microenvironment interactions in lymphoma</b> Michael R. Green, Houston, TX, US	051
	09:55 – 10:55	<b>Epigenetic basis and therapy of follicular helper T-cell lymphomas</b> François Lemonnier, Créteil, FR	052
	10:15 – 10:30	<b>Super-enhancer hypermutation in DLBCL: role of alterations in the glucocorticoid receptor pathway</b> Elodie Bal, New York, NY, US	053
<b>Polivalente room</b> East Campus USI	09:15 – 10:30	<b>SESSION 9 - LYMPHOMA IMAGING</b> Chairs: Sally F. Barrington, London, GB and Bruce D. Cheson, Bethesda, MD, US	
	09:15 – 09:30	<b>Baseline PET Radiomics Outperforms Clinical Risk Scores in Predicting Primary Mediastinal B-Cell Lymphoma Outcome: Insights from the IELSG37 Study</b> Luca Ceriani, Bellinzona, CH	054

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

**Friday, June 16**

Saturday, June 17

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

**Friday, June 16**

Saturday, June 17

	09:30 – 09:45	<b>Risk stratification of DLBCL with MVED2 score using integrative host adipose density and metabolic tumor characteristics compared to other indexes</b> Catherine Thieblemont, Paris, FR	055
	09:45 – 10:00	<b>Baseline SUV and early response, but not MTV, are associated with outcome in relapsed/refractory Hodgkin lymphoma patients treated with nivolumab in the CHECKMATE 205 trial</b> Sally F. Barrington, London, GB	056
	10:00 – 10:15	<b>Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T-cell therapy outcome</b> Brandon S. Imber, New York, NY, US	057
	10:15 – 10:30	<b>Radiomics reflecting both tumor and host features improves outcome prediction in follicular lymphoma</b> Louis Rebaud, Paris, FR	058
<b>Marquee</b>	10:30 – 11:00	<b>Coffee break</b>	
<b>Room A,</b> broadcast in Room B, Marquee, Cinema Corso and Polivalente room, East Campus USI	11:00 – 12:00	<b>SESSION 10 - HODGKIN LYMPHOMA</b> Chairs: Andrew T. Lister, London, GB and Astrid Pavlovsky, Buenos Aires, AR	
	11:00 – 11:15	<b>Genetically Distinct Pathogenesis of Epstein-Barr Virus (EBV)-positive Versus EBV-negative Classical Hodgkin (cHL) Lymphoma</b> Enrico Tiacci, Perugia, IT	059
	11:15 – 11:30	<b>Distinct Hodgkin lymphoma subtypes identified by noninvasive genomic profiling</b> Stefan K. Alig, Stanford, CA, US	060
	11:30 – 11:45	<b>Dual targeting of Hodgkin's Lymphoma by anti-CD30 CAR-T cells co-transduced with an anti-PDL1 costimulatory receptor to overcome the immunosuppressive microenvironment</b> Brunangelo Falini, Perugia, IT	061

	11:45 – 12:00	<b>The prognostic impact of clinical factors and immunoarchitectural patterns for nodular lymphocyte-predominant Hodgkin lymphoma: an international study by GLOW</b> Michael S. Binkley, Stanford, CA, US	062
<b>Marquee</b>	12:00 – 13:00	<b>Lunch time and Poster viewing</b>	
<b>Room A,</b> broadcast in all rooms	13:00 – 13:45	<b>JOHN ULTMANN MEMORIAL LECTURE</b> Supported by the American Association for Cancer Research – AACR  Laudatio: Jonathan W. Friedberg, Rochester, NY, US  <b>25 years of antibody treatments for lymphoma</b> Peter W.M. Johnson, Southampton, GB	003
<b>Room A,</b> broadcast in Cinema Corso	13:45 – 15:00	<b>SESSION 11 - MARGINAL ZONE LYMPHOMA</b> Chairs: Izidore S. Lossos, Miami, FL, US and Grzegorz S. Nowakowski, Rochester, NJ, US	
	13:45 – 14:00	<b>Marginal Zone Lymphoma International Prognostic Index (MZL-IPI): a prognostic score for the entire spectrum of marginal zone lymphomas. A FIL and SPORE-MER study</b> Stefano Luminari, Reggio Emilia, IT	063
	14:00 – 14:15	<b>Staging FDG-avidity in extranodal marginal zone lymphoma (EMZL) by disease location</b> Juan P. Alderuccio, Miami, FL, US	064
	14:15 – 14:30	<b>Rituximab and Ibrutinib Combination Is Safe and Effective in Untreated Splenic and Nodal Marginal Zone Lymphomas: Planned Subset Analysis of the IELSG47/MALIBU Phase II Study</b> Catherine Thieblemont, Paris, FR	065
	14:30 – 14:45	<b>The IELSG39 Trial: Efficacy of First-Line Chlamydia psittaci Eradication with a Six-Month Regimen of Doxycycline in Patients with Stage-I MALT Lymphoma of the Ocular Adnexae</b> Andrés J. M. Ferreri, Milan, IT	066

	14:45 – 15:00	<b>Immunotherapy alone versus chemoimmunotherapy as first-line treatment of marginal zone lymphoma (MZL): a real-world analysis</b> Adam J. Olszewski, Providence, RI, US	067
<b>Room B,</b> broadcast in Marquee	13:45 – 15:00	<b>SESSION 12 - LYMPHOMA BIOLOGY</b> Chairs: Riccardo Dalla-Favera, New York, NY, US and Gianluca Gaidano, Novara, IT	
	13:45 – 14:00	<b>BTG2 super-enhancer mutations disrupt TFAP4 binding and dysregulate BTG2 expression in Diffuse Large B-cell Lymphoma</b> Elodie Bal, New York, NY, US	068
	14:00 – 14:15	<b>Clonal architecture of relapsed or refractory follicular helper T-cell lymphoma: an ancillary study of the ORACLE trial, a LYSA study</b> François Lemonnier, Creteil, FR	069
	14:15 – 14:30	<b>Molecular characterization contributes to diagnosis and predicts outcome in primary mediastinal large B-cell lymphomas: a LYSA study</b> Vincent Camus, Rouen, FR	070
	14:30 – 14:45	<b>Gene expression profiling of t(14;18)-negative CD23+ follicle center lymphoma demonstrates activation of the IL4/JAK/STAT6 pathway and a role in its pathogenesis</b> Tim-Colin Schade, Tuebingen, DE	071
	14:45 – 15:00	<b>Immunoglobulin class dictates transformation trajectory and BCR status of MYC/BCL2 double-hit lymphoma: biology and clinical implications</b> Stefano Casola, Milan, IT	072
<b>Auditorium</b> West Campus USI	14:30 – 16:30	<b>IBSA FOUNDATION SPECIAL FORUM</b> <b>Personalized therapy in oncology</b> Moderator: Andrea Alimonti, Bellinzona, CH <i>Organized by IBSA Foundation for scientific research</i>	
	14:30 – 14:40	Institutional greetings and introduction	
	14:40 – 15:20	<b>Organoids model human disease</b> Hans Clevers, Basel, CH	

	15:20 – 16:00	<b>Unconventional approaches to cancer therapy</b> René Bernards, Amsterdam, NL	
	16:00 – 16:15	<b>Patient-specific models of multicellular oncogenic competence in metastasis</b> Arianna Baggolini, Bellinzona, CH	
	16:15 – 16:30	<b>Q&amp;A</b>	
<b>Polivalente room</b> East Campus USI	14:30 – 17:30	<b>UCLI – ICML JOINT SESSION</b> <b>LYMPHOMA RESEARCH: NEWS FROM CHINA AND EUROPE</b> <i>In collaboration with Union for China Lymphoma Investigators - UCLI</i> Honorary co-chairs: Jun Ma, Harbin, CN, Jun Zhu, Beijing, CN, Franco Cavalli, Bellinzona, CH and Julie Vose, Omaha, NE, US Executive co-chairs: Yuqin Song, Beijing, CN, Junning Cao, Shanghai, CN, Emanuele Zucca, Bellinzona, CH and Laurence L. de Leval, Lausanne, CH	
	14:30 – 14:40	Welcome by the co-chairs	
	14:40 – 15:05	<b>Introduction of Lymphoma Database of National Health Commission of the People's Republic of China</b> Weiping Liu, Beijing, CN	073
	15:05 – 15:30	<b>1998-2023 Twenty-five years of commitment to improving our understanding of lymphoma</b> Emanuele Zucca, Bellinzona, CH	074
	15:30 – 15:55	<b>Smart Start with Tislelizumab as the Front-line Treatment in Patients with High-risk Stage IIB and Advanced-stage Classical Hodgkin Lymphoma</b> Zhiming Li, Guangzhou, CN	075
	15:55 – 16:10	<b>Break</b>	
	16:10 – 16:35	<b>Role of checkpoint inhibitor in Germany</b> Peter Borchmann, Cologne, DE	076
	16:35 – 17:00	<b>New Drug Development in Lymphoma of China Is Going Global</b> Keshu Zhou, Zhengzhou, CN	077

	17:00 – 17:25	<b>New trends in lymphoma treatment in Western Countries</b> Pier Luigi Zinzani, Bologna, IT	078
	17:25 – 17:30	Conclusions remarks by the co-chairs	
<b>Room A,</b> broadcast in room B, Marquee and Cinema Corso	15:15 – 15:30	<b>Report of the 17-ICML Closed Workshop</b> Bruce D. Cheson, Bethesda, MD, US	
<b>Room A,</b> broadcast in room B, Marquee and Cinema Corso	15:30 – 17:00	<b>SESSION 13 - FOLLICULAR LYMPHOMA</b> Chairs: Jonathan W. Friedberg, Rochester, NY, US and Eva Kimby, Stockholm, SE	
	15:30 – 15:45	<b>A “Functional Cure” May be Achievable in a Subset of Patients with Follicular Lymphoma treated with chemoimmunotherapy: 15-Year Follow-Up of Phase III SWOG-S0016</b> Mazyar Shadman, Seattle, WA, US	079
	15:45 – 16:00	<b>SAKK 35/14 randomized trial of rituximab with or without ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy</b> Emanuele Zucca, Bellinzona, CH	080
	16:00 – 16:15	<b>Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study</b> Pier Luigi Zinzani, Bologna, IT	081
	16:15 – 16:30	<b>Odrone tamab in patients with relapsed/refractory follicular lymphoma (FL) grade 1–3a: Results from a prespecified analysis of the pivotal Phase II study ELM-2</b> Silvana Novelli, Barcelona, ES	082
	16:30 – 16:45	<b>Mosunetuzumab demonstrates durable responses in patients with relapsed/refractory follicular lymphoma and ≥2 prior therapies: updated analysis of a pivotal Phase II study</b> Laurie H. Sehn, Vancouver, BC, CA	083

	16:45 – 17:00	<b>Epcoritamab with rituximab + lenalidomide (R2) provides durable responses in high-risk follicular lymphoma, regardless of POD24 status</b> David Belada, Hradec Králové, CZ	084
--	---------------	---	-----

<b>Room A,</b> broadcast in room B, Marquee and Cinema Corso	17:00 – 17:30	<b>ESMO – ICML Special Lecture</b> <b>Does it matter how we name lymphomas?</b> James O. Armitage, Omaha, NE, US	085
---	---------------	--	-----

<b>Marquee</b>	17:30 – 18:00	<b>Farewell Coffee break</b>	
----------------	---------------	------------------------------	--

<b>Room A</b>	18:00 – 19:00	<b>THE BIG DEBATE</b> <b>MOVING TARGETS IN LYMPHOMA TREATMENT</b> Chair: Emanuele Zucca, Bellinzona, CH <i>Satellite symposium organised by the Foundation for the Institute of Oncology Research (IOR)</i> Supported by sponsorship from Gilead Sciences Europe Ltd. Gilead has had no input into the agenda, speaker selection or content of the presentations used at this event.	
---------------	---------------	---	--

### DEBATE 1.

**Best therapy in aggressive mantle cell lymphoma: Time for frontline chemotherapy-free regimens?**

YES - Michael L. Wang, Houston, TX, US

NO - Martin Dreyling, Munich, DE

### DEBATE 2.

**Towards a cure for relapsing/refractory diffuse large B cell lymphoma: Bispecific antibodies better than CAR-T cells?**

YES - Laurie H. Sehn, Vancouver, BC, CA

NO - Gloria Iacoboni, Barcelona, ES

### DEBATE 3.

**Frontline treatment of advanced Hodgkin lymphoma: Should A+AVD replace PET-driven strategies?**

YES - Stephen M. Ansell, Rochester, MN, US

NO - Peter Borchmann, Cologne, DE

## SATURDAY, JUNE 17

<b>Room A</b>	08:45 – 10:15	<b>SESSION 14 - NOVEL AGENTS</b> Chairs: M. Lia Palomba, New York, NY, US and Anastasios Stathis, Bellinzona, CH	
---------------	---------------	---	--

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

**Friday, June 16**

Saturday, June 17

Tuesday, June 13

Wednesday, June 14

Thursday, June 15

**Friday, June 16**

Saturday, June 17



08:45 – 09:00	<b>High Complete Response Rate With TNB-486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Follicular Lymphoma: Interim Results from an Ongoing Phase 1 Study</b> Ranjit Nair, Houston, TX, US	086
09:00 – 09:15	<b>Phase 1b/2a study of AZD4573 (CDK9i) and acalabrutinib in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)</b> Alexey Danilov, Duarte, CA, US	087
09:15 – 09:30	<b>Phase 1 Study Of JNJ-67856633, A First-In-Human MALT1 Inhibitor, In Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL) And Chronic Lymphocytic Leukemia (CLL)</b> Mark Hertzberg, Randwick, NSW, AU	088
09:30 – 09:45	<b>Enhancer of zeste homolog 2 (EZH2) inhibitor SHR2554 in relapsed or refractory (r/r) peripheral T-cell lymphoma (PTCL): updated outcomes from the first-in-human phase 1 study</b> Yuqin Song, Beijing, CN	089
09:45 – 10:00	<b>Open-label phase 1/2 study of CC-99282, a cereblon E3 ligase modulator (CELMoD) agent ± rituximab, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)</b> Jean M. Michot, Villejuif, FR	090
10:00 – 10:15	<b>Combining CD19-4-1BBL (R07227166) with glofitamab is safe and shows early efficacy in patients suffering from relapsed or refractory B-cell Non-Hodgkin Lymphoma</b> Michael Dickinson, Melbourne, AU	091

**Room B**

08:45 – 10:15	<b>SESSION 15 - IMMUNOTHERAPY FOR AGGRESSIVE LYMPHOMAS</b> Chairs: Urban Novak, Bern, CH and Catherine Thieblemont, Paris, FR
---------------	--

08:45 – 09:00	<b>Glofitamab plus polatuzumab vedotin demonstrates durable responses and a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma</b> Martin Hutchings, Copenhagen, DK	092
09:00 – 09:15	<b>Odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL): Results from a prespecified analysis of the pivotal Phase II study ELM-2</b> Michelle Poon, Singapore, Singapore, SG	093
09:15 – 09:30	<b>Subcutaneous epcoritamab induces deep, durable complete remissions in relapsed/refractory large B-cell lymphoma: longer follow-up from the pivotal EPCORE NHL-1 trial</b> Catherine Thieblemont, Paris, FR	094
09:30 – 09:45	<b>Glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal Phase II study</b> Michael Dickinson, Melbourne, AU	095
09:45 – 10:00	<b>Bispecific anti-CD20/19 CAR-T - zamto-cabtagene autoleucel for relapsed/refractory DLBCL - Interim analysis results of DALY-II-USA Study</b> Matthew Ulrickson, Gilbert, AZ, US	096
10:00 – 10:15	<b>Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Final Analysis of ALYCANTE, a Phase 2 LYSA Study</b> Roch Houot, Rennes, FR	097

**Room A**

10:15 – 11:30	<b>SESSION 16 - LATE BREAKING ABSTRACTS</b> Chairs: Franco Cavalli, Bellinzona, CH and Martin Dreyling, Munich, DE	
10:15 – 10:30	<b>Genome-wide association study of childhood Burkitt Lymphoma in East Africa identifies a novel germline susceptibility locus on chromosome 21</b> Sam M. Mbulaiteve, Rockville, MD, US	LBA1

10:30 – 10:45	<b>Ibrutinib plus BR or R-CHOP in previously treated patients with Follicular or Marginal Zone Lymphoma: the phase 3 SELENE Study</b> Loretta J. Nastoupil, Houston, TX, US	LBA2
10:45 – 11:00	<b>Lisocabtagene maraleucel (liso-cel) in R/R MCL: primary analysis results from the MCL cohort of the single-arm, multicenter, seamless design TRANSCEND NHL 001 study</b> Michael L. Wang, Houston, TX, US	LBA3
11:00 – 11:15	<b>TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)</b> Franck Morschhauser, Lille, FR	LBA4
11:15 – 11:30	<b>BrECADD is non-inferior to eBEACOPP in patients with advanced stage classical Hodgkin Lymphoma: efficacy results of the GHSG phase III HD21 trial</b> Peter Borchmann, Cologne, DE	LBA5

**Room B**

10:15 – 11:05	<b>“FOCUS ON...” SESSION</b> <b>Long term results of CLL trials</b> Chairs: Barbara F. Eichhorst, Cologne, DE and John Seymour, Melbourne, AU	
10:15 – 10:25	<b>5-Year (Y) Follow-up of a Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) as Initial Therapy for Younger CLL Patients (Pts)</b> Inhye E. Ahn, Boston, MA, US	152
10:25 – 10:35	<b>Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL</b> Jacob D. Soumerai, Boston, MA, US	153
10:35 – 10:45	<b>Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) CLL/SLL: Extended follow-up of the SEQUOIA study</b> Mazyar Shadman, Seattle, WA, US	154

10:45 – 10:55	<b>Fixed-duration ibrutinib + venetoclax in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study</b> Paolo Ghia, Milan, IT	155
---------------	---	-----

10:55 – 11:05	<b>MURANO: Final 7 year follow up and retreatment analysis in venetoclax-rituximab (VenR)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)</b> Arnon P. Kater, Amsterdam, NL	156
---------------	---	-----

**Room A**

11:30 – 11:50	<b>17-ICML HIGHLIGHTS</b> <b>“Take Home Messages”</b> Martin Dreyling, Munich, DE	
---------------	---	--

**Room A**

11:50 – 12:00	<b>CLOSURE AND FAREWELL</b> Franco Cavalli, Bellinzona, CH	
---------------	---	--

**Room B**

13:30 – 18:00	<b>VI INTERNATIONAL WORKSHOP ON CANINE LYMPHOMA</b> <b>FOCUS ON CANINE T CELL LYMPHOMA</b> <i>organized by the European Canine Lymphoma Network (open to all 17-ICML attendees)</i> Co-chairs: Luca Aresu, Turin, IT, Stefano Comazzi, Milan, IT, Fausto Guscelli, Zurich, CH and Laura Marconato, Bologna, IT	
---------------	---	--

## TRANSPORT INFORMATION

Attendees who have booked their accommodation in Canton Ticino will receive the Ticino Ticket, a public transport ticket, valid for the entire duration of their stay on all public transport in Ticino (buses, trains and postal buses of the “Arcobaleno Community”). The Ticino Ticket cannot be purchased: it is free of charge and must be requested upon hotel check-in.

Thanks to the efficient public transportation network, participants may now reach Lugano in maximum 30 minutes from the railway stations situated near to the hotels booked through our partner Amiconi Consulting SA. Public transport timetable covers the entire ICML schedule, allowing participants to follow both the scientific and industry programs of the conference.

The Organizing Committee promotes the use of public transport with the aim to limit emissions on the territory and avoid unnecessary city traffic. The Committee asks our participants for maximum collaboration and sharing of this project.

However, for those hotels that are not served by public transports, morning and evening transfers at convenient times to follow the scientific and industry programs have been organized.

The bus schedule and timetable are available at the ICML official website ([www.icml.ch](http://www.icml.ch)) and at the Transport Info Desk.

### 17-ICML SHUTTLE SERVICE

A shuttle service connects the Conference locations with the following timetable:  
- on Tuesday, June 13, from 17:00 to 21:00  
- from Wednesday, June 14 to Friday, June 16, from 07:30 to 21:30  
- on Saturday, June 17, from 07:30 to 09:00  
Please note that, on this service, attendees with physical disabilities have precedence.

### FURTHER INFORMATION

Lugano long lake will be closed to traffic on Friday, June 16 from 20:00.

### Insurance

The 17-ICML Organizers bear no responsibility for untoward events in connection with, before, during and after the Conference. Participants are strongly advised to take out their own personal and travel insurance coverage.

**NB: charge of replacement of lost badge:  
CHF 100.-**

## ONSITE CONTACT DETAILS

### 17-ICML Registration and Information Desk

Monday, June 12	only by appointments, only for groups
from Tuesday, June 13 to Friday, June 16	07:00 – 19:30
Saturday, June 17	07:00 – 13:00

### Contacts during the Conference

Cristiana Brentan (scientific program and general information)	Ph. +41 58 666 73 09
Federica Cariglia (communication and press)	Ph. +41 79 938 0356
Orietta Lugli (exhibition, satellite symposia, ancillary meetings)	Ph. +41 58 666 73 13
Stéphanie Pedrioli (faculty)	Ph. +41 58 666 70 14
Chiara Saporiti (registrations and accounting)	Ph. +41 58 866 66 68

# THE EUROPEAN SCHOOL OF ONCOLOGY

is an independently funded **non profit organisation**  
dedicated to **oncology education and training**



Extensive learning programmes to **reduce disparities**  
and **promote multidisciplinary cancer care.**